Myelodysplastic Syndrome Treatment Market Insights
Rising public awareness about Myelodysplastic Syndromes (MDS) and its early diagnosis and availability of new treatment options for MDS are expected to drive growth of the market over the forecast period. Moreover, early diagnosis of MDS is important because it significantly increases the quality of life in patients, reducing the chances of recurrent blood transfusion and in more severe cases, as in 30% of the time, the evolution of the disease to leukemia. Government organizations and drug manufacturing companies are focusing on spreading awareness about the disease by providing funding and conducting awareness programs. For instance, in October 2018, Grupo Biotoscana, a Latin American biopharmaceutical company conducted campaign to honor Myelodysplastic Syndrome World Awareness Day, which is celebrated on 25th October. GBT Grupo Biotoscana launched a campaign to raise awareness and educate about disease throughout the month.
The global myelodysplastic syndrome treatment market was valued at US$ 2,324.8 million in 2018, and is expected to exhibit a CAGR of 8.9% during the forecast period (2019–2027).
Figure 1. Global Myelodysplastic Syndrome Treatment Market Share (%), By Drug Class
Source: Coherent Market Insights Analysis (2019)
Increasing regulatory approval for drugs for treating MDS is expected to be a driving factor contributing growth of the global myelodysplastic syndrome treatment market over the forecast period
Increasing regulatory approvals is expected to drive growth of the global myelodysplastic syndrome treatment market over the forecast period. For instance, in November 2018, Lupin received the U.S. FDA approval for its Decitabine for Injection, 50 mg/vial, single-dose vial, a generic version of Otsuka Pharmaceutical Co. Ltd.'s Dacogen for Injection, 50 mg/vial, single-dose vial. Lupin’s generic version is indicated for the treatment of patients with myelodysplastic syndromes (MDS), which includes previously treated and untreated, de novo, and secondary MDS of all French-American-British subtypes.
Increasing launch and approval of Azacitidine in key region is expected to drive growth of Azacitidine segment of myelodysplastic syndrome treatment market over the forecast period. For instance, in February 2018, BeiGene, Ltd. announced the commercial availability of VIDAZ (azacitidine for injection) in China. VIDAZA is approved in China for patients with intermediate-2 / high-risk myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) with 20-30% bone marrow blasts, and chronic myelomonocytic leukemia (CMML). It is marketed in China by BeiGene under an exclusive license from Celgene Corporation.
Increased complexity of MDS disease and its true diagnosis among the patients generates major hurdle in the development of effective MDS treatment, which is expected to hamper the global myelodysplastic syndrome treatment market growth
MDS represent several different conditions, as it is not just a single disease, but it is grouped together by several clinical characteristics. According to the data published in the Hematology journal of American Society of Hematology Education Program in December 2017; the type and severity of hematopoietic dysfunction in MDS are highly variable, and the kinetics of disease progression are difficult to predict.
Moreover, genetic characteristics of MDS are powerfully associated with clinical phenotype. An enhanced understanding of the regulatory logic of MDS genetics may stimulate refined and biologically based diagnostic and monitoring schema that may be integrated into clinical practice.
Global Myelodysplastic Syndrome Treatment Market- Regional Analysis
Based on region, the global myelodysplastic syndrome treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America is expected to hold a dominant position in the market over the forecast period, owing to presence of major players and non-profit organizations in the region that are focused on launching new programs and awareness campaigns to educate people about gout disease and help healthcare practitioners in the treatment of MDS. Among North America, the U.S. is expected to witness significant growth over the forecast period, owing to rising awareness among the U.S. population about MDS. For instance, according to the American Cancer Society 2018 data, the number of people diagnosed with myelodysplastic syndromes (MDS) in the U.S. each year varies between 10,000 to 30,000 and addition of around 55,000 new cases each year.
Europe is expected to witness significant growth over the forecast period, owing to rising government initiatives for diagnosis and treatment of disease. For instance, in 2014, the European LeukemiaNet WP8 promoted a program aiming at developing and continuously updating evidence- and consensus-based guidelines to provide clinical practice recommendations for standardized diagnostic and prognostic procedures and for an appropriate choice of therapeutic interventions in adult patients with primary MDS.
Figure 2: Global Myelodysplastic Syndrome Treatment Market Share (%), By Region
Source: Coherent Market Insights Analysis (2019)
Global Myelodysplastic Syndrome Treatment Market - Competitive Landscape
Key players operating in the global myelodysplastic syndrome treatment market include Celgene Corporation, Otsuka Pharmaceutical Co., Ltd. Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Ltd., Mylan NV, Cipla Limited, Acceleron Pharma, Inc., Aprea Therapeutics, FibroGen Inc., Onconova Therapeutics Inc., and Geron